ProQR to Present at Cowen and Company 40th Annual Health Care Conference
February 24, 2020 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
May 08, 2019 17:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 03, 2018 17:15 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...
Gene Modification Therapy Market to See 49.9% Annual Growth Through 2023
September 18, 2018 06:00 ET
|
BCC Research
WELLESLEY, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Recent advancements in genetic modification, including better delivery systems, more efficient and durable gene expression constructs, and...
Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations
September 17, 2018 08:30 ET
|
Celsion CORP
Lambertson brings executive experience to the newly created position, reinforcing Celsion’s commitment to its strategic communications and investor relations objectives ...
Celsion Announces First Patient Randomized in the Gene-Mediated Immunotherapy (GEN-1) Study of Newly Diagnosed Stage III/IV Ovarian Cancer Patients
September 06, 2018 08:00 ET
|
Celsion CORP
OVATION II Study Will Evaluate Initial and Maintenance Dosing of GEN-1 on Progression-Free Survival in a Two-Arm, Randomized Trial of Up to 130 Patients LAWRENCEVILLE, N.J., Sept. 06, 2018 (GLOBE...